Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q2 EPS of ($0.14), $0.02 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $38.01 million versus the consensus estimate of $35.23 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.